Therapeutic Response

PD-L1 (CPS) >= 10 status confers therapeutic sensitivity to Pembrolizumab in patients with Adenocarcinoma of the Gastroesophageal Junction.

Statements

Source and description

Keytruda (pembrolizumab) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to pembrolizumab for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS >=10), as determined by an FDA-approved test.